RNF216 as a Promising Biomarker for Prognosis, Immunotherapy, and Chemotherapy in LIHC: A Comprehensive Pan-Cancer...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• RNF216, an E3 ubiquitin ligase, is implicated in disease development.
• Its comprehensive role in pan-cancer progression remains underexplored.

Purpose of the Study:

• To systematically investigate the role of RNF216 in pan-cancer development.
• To evaluate RNF216's diagnostic and prognostic significance across various cancers, with a focus on liver hepatocellular carcinoma (LIHC).

Main Methods:

• Utilized public datasets from TCGA, GEO, and HPA.
• Performed bioinformatic analyses using R, STRING, TISIDB, and TISCH.
• Validated RNF216's function in LIHC via CCK-8 and other experiments.

Main Results:

• RNF216 expression and mutation rates are elevated in most tumor tissues, particularly LIHC.
• RNF216 shows significant diagnostic and prognostic value, correlating with tumor mutational burden, microsatellite instability, and clinicopathologic features.
• RNF216 influences tumor growth via mitosis, cell death, DNA damage, and is linked to immune cell infiltration; siRNA-mediated knockout inhibits proliferation and invasion in liver cancer cells.

Conclusions:

• RNF216 is significantly upregulated in diverse tumors, including LIHC, highlighting its critical role in cancer diagnosis and prognosis.
• Targeting RNF216 presents a promising strategy for enhancing immunotherapy and chemotherapy efficacy.